Health Care

Since the development of the first vaccine by Edward Jenner in 1796, we have seen tremendous progress in our ability to prevent deadly childhood infections.

Regulatory review processes are not keeping up with rapidly advancing science and are making the environment for developing new treatments and preventions for deadly and debilitating diseases more difficult.

Bernard Siegel, executive director of the Genetics Policy Institute and co-chair of the World Stem Cell Summit, discusses the latest on NIH funding for embryonic stem cell research and tells us why he believes stem cell research is the future of medicine.

The buzz at BIO India hones in on the lack of clarity and consistency within the clinical trials process

Phyllis Arthur interviews Colonel Randall Larsen, CEO of the WMD Center, on the threat of a pandemic as portrayed in the movie Contagion which opens in theatres nationwide today.

Jack discusses her greatest accomplishments, advice for industry leaders, and the promise of biotech. Pulmatrix is a clinical trial stage biotech company based in Lexington, Mass.

What is ALS? How widespread is the disease? Are there any treatments for ALS? Dr. Steven Perrin discusses his organization's approach to stopping ALS.

Did you know that there is a community of sick and disabled women, children, and men that is so large that it outnumbers all of those with cancer and AIDS combined worldwide?

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

Dr. Napoleone Ferrara was named the 2011 winner of The Dr. Paul Janssen Award for Biomedical Research for his research on angiogenesis, the process of new blood vessel formation, and the isolation and cloning of vascular endothelial growth factor.

Dr. Augustus White is author of “Seeing Patients: Unconscious Bias in Health Care” and a pioneer in equitable care. Dr. White will be delivering the keynote address at this year’s Diversity Summit at the 2011 BIO International Convention in Washington, D.C.

GlycoMimetics’ Rachel King discusses the prevalence of sickle cell disease and urgency to find treatments.

Dr. Tettelin discusses his research in reverse vaccinology and as a pioneer of the pan-genome concept.

Moree discusses the Forum and the importance of partnering to improving the health of people in developing countries.

June 9 2014
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the draft guidance issued by the Food and Drug Administration (FDA) on April 9, 2014, entitled “Draft Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff: Meetings with the Office of Orphan Products Development.”
May 27 2014
 The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance for Industry on Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway.
May 20 2014
The importance of supporting biomedical research and innovation and the development of new therapies cannot be overstated. Today, we face increasing competition around the globe to overtake U.S. world leadership in biomedical innovation. Even in this time of budgetary constraint, it is crucial that we not allow this to happen. We cannot afford to lose the next generation of discoveries that address one of the nation’s leading cost drivers – chronic and debilitating disease.
May 2 2014
As with the FDA’s previous Guidance on this topic (2009 Guidance),1 BIO continues to support FDA‘s clarification of its views on the dissemination of medical journal articles and medical or scientific reference publications that contain truthful and non-misleading information, including new information about the uses of approved drugs, biologics and medical devices. In addition, BIO supports FDA’s inclusion in this Revised Draft Guidance of recommendations regarding manufacturer provision of medical journals and texts, as well as Clinical Practice Guidelines (CPGs), that similarly contain truthful and non-misleading information, including new information, about the uses of approved drugs, biologics, and medical devices.
March 14 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the "Proposed Rule: Supplemental Applications Proposing Labelling Changes for Approved Drugs and Biological Products."
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
March 25 2014
The Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF) commend Indiana Governor Mike Pence for signing legislation today designed to create a pathway for the substitution of interchangeable biologic medicines.
March 5 2014
Many of the provisions included in this budget proposal would jeopardize the continued biotech research and development that is necessary to find cures and breakthrough medicines for patients living with debilitating and life-threatening diseases. 
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed